2029 年全球Peptide治療市場、藥物劑量、價格和臨床試驗見解

到 2029 年，全球Peptide治療市場預計將達到 600 億美元。

在充滿活力的製藥產業中，Peptide類藥物作為創新和治療潛力的指標脫穎而出。 這些特殊的治療劑因其廣泛的應用和獨特的優勢而引起了人們的廣泛關注。 □藥物提供了一種精確且個人化的治療方法，從治療代謝紊亂到治療癌症等複雜疾病。 因此，對於製藥業來說，了解Peptide在市場上日益增長的重要性以充分發揮其潛力變得非常重要，並且了解它所具有的革命性影響也變得非常重要。

曾經隱藏在小分子和大蛋白療法的陰影下的Peptide最近已成為製藥領域的新增長前沿。 Peptide已展現出治療、診斷和治療功效，開啟了精準醫學的新時代。 這些適應性分子透過提供有針對性的治療介入措施，在治療多種疾病狀態中發揮重要作用。 除了其治療潛力之外，Peptide還照亮了診斷領域，充當檢測特定生物標記和疾病的燈塔。 治療和診斷能力的融合催生了治療診斷學的進化概念，其中□既充當治療師又充當嚮導，為個性化和有效的醫療保健解決方案指明了道路。

研究和技術的進步推動了Peptide藥物開發的不斷發展。 組合化學和高通量篩選有助於發現具有藥物潛力的新Peptide序列。 此外，Peptide合成製程的進步提高了生產效率，並解決了過去有關可擴展性和成本效益的問題。 計算工具和結構生物學在Peptide設計中的整合加速了先導化合物的鑑定並縮短了藥物開發所需的時間。

將人工智慧融入多□藥物研發，開啟了效率與創新的新時代。 機器學習演算法分析大量資料集並預測具有高結合親和力的Peptide結構，從而提高候選藥物的成功率。 此外，人工智慧還可以幫助識別潛在的不良事件並優化藥物動力學特性，有助於Peptide治療藥物整體品質的提升。 ProteinQure 等製藥公司正在使用計算工具來開發廣泛的Peptide療法組合，而 Space Peptides 等其他製藥公司正在使用機器來設計和製造高品質的Peptide藥物。我們提供允許使用學習和人工智慧工具的合約服務。

全球Peptide治療產品線的快速擴張證明了主要製藥公司對Peptide藥物的興趣日益濃厚。 此外，近幾個月來，製藥業的研究合作和策略聯盟激增，其中一些涉及禮來（Eli Lilly）和阿斯特捷利康（AstraZeneca）等著名製藥公司。 認識到Peptide在解決未滿足的醫療需求方面的潛力，領先公司正在積極尋求透過合資、許可協議和收購來擴大其Peptide產品組合，從而使他們能夠匯集資源並整合知識，以加速Peptide的開發和商業化藥物。

多□藥物有望在全球醫藥市場的未來前景中發揮重要作用。 隨著分子層面闡明疾病原因不斷取得進展的同時，Peptide的精準靶向能力將得到體現，並將成為個人化醫療的基石。 □工程的持續進步，加上人工智慧的引入，幾乎肯定會導致高效且耐受性良好的治療方法的開發。 隨著製藥業轉向以患者為中心的範式，Peptide藥物的適應性和特異性使它們成為不斷變化的醫療保健領域的領導者。 Peptide的治療適應性和高安全性使其成為尋求滿足患者多樣化醫療需求的製藥公司的有吸引力的選擇。

總之，Peptide醫學領域的旅程揭示了廣泛的創新和可能性。 當我們進入醫學新時代時，Peptide不僅僅是治療劑或診斷劑，而且正在成為醫療保健範式轉變的先兆。 未來，Peptide將在個人化醫療、標靶治療和不斷擴大的精準醫療領域中發揮關鍵作用。 人工智慧等尖端技術與Peptide固有的多樣性相結合，為無與倫比的發展打開了大門。 □醫學的不斷發展的故事描繪了一個令人著迷的未來願景，其中這些分子繼續突破醫學可能性的界限，提供創新的治療方法和樂觀的前景。

本報告分析了全球Peptide治療市場，預測了全球和區域市場規模趨勢（年度/季度），並提供了各種Peptide臨床試驗進展資訊（按國家和適應症）。我們正在調查以下資訊主要Peptide產品的資訊（專利、可用性、成本、劑量、銷售等）、主要開發平台和主要公司簡介。

目錄

第一章多Peptide藥物概述

• 歷史、發展、演變
• 核准的多Peptide藥物

第 2 章Peptide藥物：治療、診斷、治療診斷的潛力、對市場的影響

• 治療潛力與市場影響
• 診斷潛力與市場影響
• 治療潛力與市場影響

第三章□類藥物的全球臨床試驗與市場趨勢：依適應症分類

• 遺傳性疾病
• 癌症
• 微生物感染
• 自體免疫疾病
• 代謝紊亂
• 神經退化性疾病

第 4 章基於Peptide的治療方法

• Peptide類激素
• Peptide藥物結合物
• Peptide疫苗
• Peptide激動劑
• Peptide適配體
• 多□抗體

第五章全球Peptide治療市場展望

• 當前市場趨勢與驅動因素
• 未來的發展道路

第六章多Peptide治療藥物市場狀況：依地區

• 美國
• 歐盟
• 中國
• 日本
• 韓國
• 英國
• 印度
• 中東
• 加拿大
• 澳大利亞

第七章全球Peptide療法臨床試驗概述

• 依國家/地區
• 適應症
• 階段
• 優先狀態
• 治療課程

第 8 章：已上市Peptide藥物的討論：專利、可用性、成本、劑量和銷售的見解

• Bylvay
  • 摘要
  • 價格趨勢與用量分析
  • 銷售分析
• Parsabiv
• Bydureon BCise
• Linzess
• Increlex
• Terlivaz
• Empaveli
• Voxzogo
• Imcivree
• Trulicity
• Ozempic
• Wegovy
• Tresiba
• Rybelsus
• Xultophy
• Victoza
• Ryzodeg
• Fiasp
• Lantus
• Toujeo

第九章□治療藥物開發技術與平台

• Biodrug Design Accelerator - Fujitsu/PeptiDream
• T-Win (R) Technology - IO Biotech
• Numatech - Numaferm
• ProteinStudio - ProteinQure
• The Magnifier NφΦ (TM) - Nuritas
• PepPower - GenScript
• Unnamed Peptide Platform - Zealand Pharma
• PDPS (Peptide Discovery Platform System) - PeptiDream
• Veneno Suite - Veneno Technologies
• SmartDepot (TM) Technology - Peptron
• Bicycles - Bicycle Therapeutics
• RALA Technolgy - pHion Therapeutics
• Discovery Platform - Orbit Discovery
• Imotopes - Imcyse
• Nautilus - Peptilogics
• Swarm Intelligence 2.0 - Pepticom
• streaMLine Platform - Gubra
• Precision Endocrine Peptides (PEPs) - MBX Biosciences
• pHLIP (pH-Low Insertion Peptides) - pHLIP
• alphalex - Cybrexa

第10章環□臨床試驗分析：依國家、適應症及分期劃分

• 調查
• 臨床前
• 第一階段
• 第一/二期
• 第二階段
• 第二/第三階段
• 第三階段
• 註冊前
• 已註冊
• 已上市

第11章Peptide激素臨床試驗分析：依國家、適應症及分期劃分

第十二章Peptide臨床試驗分析：依國家、適應症及分期

第十三章胰高血糖素樣Peptide臨床試驗分析：依國家、適應症及分期劃分

第 14 章寡□臨床試驗分析：依國家、適應症和分期

第十五章脂□臨床試驗分析：依國家、適應症及分期

第 16 章二□臨床試驗分析：依國家、適應症和分期劃分

第十七章縮□臨床試驗分析：依國家、適應症和分期劃分

第十八章糖□臨床試驗分析：依國家、適應症及分期

第十九章Peptide疫苗臨床試驗分析：依國家、適應症及分期劃分

第 20 章Peptide片段臨床試驗分析：依國家、適應症和分期劃分

第 21 章阿片□臨床試驗分析：依國家、適應症和分期劃分

第22章利鈉□臨床試驗分析：依國家、適應症及分期劃分

第 23 章神經Peptide臨床試驗分析：依國家、適應症和分期

第24章抗菌陽離子Peptide臨床試驗分析：依國家、適應症及分期劃分

第 25 章Peptide水解□臨床試驗分析：依國家、適應症和分期劃分

第26章Peptide適體

第27章細胞間訊號Peptide臨床試驗分析：依國家、適應症及分期劃分

第28章Peptide類抗生素臨床試驗分析：依國家、適應症及分期劃分

第29章Peptide藥物偶聯物臨床試驗分析：依國家、適應症及分期劃分

第30章雙環□臨床試驗分析：依國家、適應症及分期劃分

第31章多種Peptide臨床試驗分析：依國家、適應症及分期劃分

第32章競爭格局

• AbbVie
• Adocia
• Amgen
• Antlia Bioscience
• AsclepiX Therapeutics
• AstraZeneca
• Bicycle Therapeutics
• Biohaven Labs
• Bristol-Myers Squibb
• Carmot Therapeutics
• Eli Lilly and Company
• Ferring Pharmaceuticals
• Gan&Lee Pharmaceuticals
• GEROPHARM
• Hanmi Pharmaceutical
• HEC Pharm
• Heidelberg Pharma AG
• ImCyse
• Janux Therapeutics
• Kine Sciences
• Lactocore
• Maxwell Biosciences
• Merck & Co
• Novartis
• Novo Nordisk
• Oryn Therapeutics
• Palatin Technologies
• PeptiDream
• Pfizer
• Priavoid
• Primary Peptides
• Protagonist Therapeutics
• Roche
• Sanofi
• Sapience Therapeutics
• Seagen
• Shaanxi Micot Technology Co
• Stuart Therapeutics
• Takeda
• Zealand Pharma

“Global Peptide Therapeutics Market, Drug Dosage, Price & Clinical Trials Insight 2029” Reports Findings & Highlights:

• Global Peptide Therapeutics Market Opportunity: > USD 80 Billion By 2029

• Global & Regional Peptide Therapeutics Market Outlook

• Insight On Peptides In Clinical Trials By Country, Indication & Phase: > 900 Peptides In Trials

• Comprehensive Insight On Peptides Drugs Available in Market: > 200 Peptides

• Marketed Peptide Drugs Insight: Patent, Availability, Cost, Dosage, & Sales Insight

• Global, Regional, Annual & Quarterly Sales Insights

• Peptide Therapeutics Development Technologies Platform

• Global Peptide Drugs Clinical Research & Market Trends by Indication

In the dynamic pharmaceutical landscape, peptide drugs stand out as an indicator of innovation and therapeutic potential. These exception therapeutic agents have received a lot of interest due to their wide range of applications and distinct advantages. Peptide drugs provide a precise and personalized approach to therapy, from treating metabolic abnormalities to tackling complex diseases like cancer. As a result, it has become important for the pharmaceutical industry to understand the growing significance of peptides in the market to exploit their full potential, and also the revolutionary influence they are poised to have in the constantly evolving environment of healthcare.

Once overshadowed by small molecule and large protein based therapeutics, peptides have emerged as the new growth frontier of the pharmaceutical realm in the recent years. They have demonstrated therapeutic, diagnostic and theranostic properties, ushering in a new era of precision medicine. These adaptable molecules serve a critical role in treating a wide range of medical conditions by providing targeted therapeutic interventions. Beyond their treatment prowess, peptides illuminate the diagnostic landscape, serving as beacons in the detection of specific biomarkers and diseases. The convergence of therapeutic and diagnostic capabilities gives rise to the evolutionary concept of theranostics, where peptides act as both healers and guides, navigating the path toward personalized and effective healthcare solutions.

The continuous evolution of peptide drug development is fuelled by advancements in research and technology. Combinatorial chemistry and high-throughput screening have aided in the discovery of new peptide sequences with medicinal promise. Furthermore, advances in peptide synthesis processes have increased manufacturing efficiency, addressing historical issues with scalability and cost-effectiveness. The integration of computational tools and structure biology in peptide design has sped up the identification of lead compounds, reducing the time required for drug development.

The incorporation of artificial intelligence in peptide drug development has ushered in a new era of efficiency and innovation. Machine learning algorithms analyze vast datasets, predicting peptide structures with high binding affinities and enhancing the success rate of drug candidates. Additionally, AI helps in the identification of potential adverse events and optimization of pharmacokinetic properties, contributing to the overall quality of peptide therapeutics. Pharmaceutical companies such as ProteinQure have developed an extensive portfolio of peptide therapeutics using computational tools, while others like Space Peptides provide contract services to grant access to their machine learning and AI tools to design and produce premium peptide drugs.

The escalating interest of large pharmaceutical companies in peptide drugs is evident from the rapidly expanding global pipeline of peptide therapeutics. In addition, a surge of collaborations and strategic partnerships has been observed in the recent months within the pharmaceutical industry, some of these involving prominent pharmaceutical companies including Eli Lilly and AstraZeneca. Recognizing the potential of peptides to address unmet medical needs, prominent companies are aggressively seeking to expand their peptide portfolios through joint ventures, licensing agreements and acquisitions, which allow resource pooling and utilization of combined knowledge, thereby accelerating the development and commercialization of peptide drugs.

Peptide drugs are expected to play a significant role in the future landscape of the global pharmaceutical market. The growing understanding of disease causes at molecular levels coincides with the precision targeting abilities of peptides, making them a cornerstone in personalized medicine. Continuous advances in peptide engineering, together with the incorporation of AI, will almost certainly result in the development of highly effective and well-tolerated treatments. As the pharmaceutical industry move toward patient-centric paradigm, the adaptability and specificity of peptide drugs positions them as frontrunners in addressing the shifting healthcare landscape. Peptides' adaptability across therapeutic areas, paired with their good safety rating, makes them an appealing choice for pharmaceutical companies seeking to fulfil patients' medical diverse needs.

In conclusion, the journey through the realm of peptide drugs reveals an extensive array of innovation and potential. As we approach a new era in pharmaceuticals, peptides appear as more than merely therapeutic and diagnostic agents, but also as forerunners of a paradigm shift in healthcare. Peptides will play a crucial role in personalized medicine, targeted therapeutics, and the ever-expanding panorama of precision healthcare in the future. The combination of cutting-edge technology like AI with the inherent versatility of peptides opens the door to exceptional developments. The expanding peptide drugs narrative pains a captivating vision of a future in which these molecules continue to push the bounds of medical possibility, delivering innovative treatments and optimisms on the horizon.

Table of Contents

1. Introduction to Peptide Drugs

• 1.1. History, Development & Evolution
• 1.2. Approved Peptide Drugs

2. Peptide Drugs - Therapeutic, Diagnostic & Theranostic Potential & Market Implications

• 2.1. Therapeutic Potential & Market Implications
• 2.2. Diagnostic Potential & Market Implications
• 2.3. Theranostic Potential & Market Implications

3. Global Peptide Drugs Clinical Research & Market Trends by Indication

• 3.1. Inheritable Genetic Diseases
• 3.2. Cancer
• 3.3. Microbial Infections
• 3.4. Autoimmune Disorders
• 3.5. Metabolic Disorders
• 3.6. Neurodegenerative Diseases

4. Peptide Based Therapeutic Approaches

• 4.1. Peptide Hormone Drugs
• 4.2. Peptide Drug Conjugates
• 4.3. Peptide Vaccines
• 4.4. Peptide Agonists
• 4.5. Peptide Aptamers
• 4.6. Peptide Antibody

5. Global Peptide Therapeutics Market Outlook

• 5.1. Current Market Trends & Drivers
• 5.2. Future Growth Avenues

6. Peptide Therapeutics Market Landscape by Region

• 6.1. US
• 6.2. EU
• 6.3. China
• 6.4. Japan
• 6.5. South Korea
• 6.6. UK
• 6.7. India
• 6.8. Middle East
• 6.9. Canada
• 6.10. Australia

7. Global Peptide Therapeutics Clinical Trials Overview

• 7.1. By Country
• 7.2. Indication
• 7.3. Phase
• 7.4. Priority Status
• 7.5. Therapy Class

8. Marketed Peptide Drugs Insight - Patent, Availability, Cost, Dosage, & Sales Insight

• 8.1. Bylvay
  • 8.1.1. Overview
  • 8.1.2. Pricing & Dosage Analysis
  • 8.1.3. Sales Insight
• 8.2. Parsabiv
  • 8.2.1. Overview & PatentS Insight
  • 8.2.2. Pricing & Dosage Analysis
  • 8.2.3. Sales Insight
• 8.3. Bydureon BCise
  • 8.3.1. Overview & Patent Insight
  • 8.3.2. Pricing & Dosage Analysis
  • 8.3.3. Sales Insight
• 8.4. Linzess
  • 8.4.1. Overview & Patent Insight
  • 8.4.2. Pricing & Dosage Insight
  • 8.4.3. Sales Insight
• 8.5. Increlex
  • 8.5.1. Overview & Patent Insight
  • 8.5.2. Pricing & Dosage Insight
  • 8.5.3. Sales Analysis
• 8.6. Terlivaz
  • 8.6.1. Overview & Patent Insight
  • 8.6.2. Pricing & Dosage Insight
  • 8.6.3. Sales Analysis
• 8.7. Empaveli
  • 8.7.1. Overview & Patent Insight
  • 8.7.2. Pricing & Dosage Insight
  • 8.7.3. Sales Analysis
• 8.8. Voxzogo
  • 8.8.1. Overview & Patent Insight
  • 8.8.2. Pricing & Dosage Insight
  • 8.8.3. Sales Analysis
• 8.9. Imcivree
  • 8.9.1. Overview & Patent Insight
  • 8.9.2. Pricing & Dosage Insight
  • 8.9.3. Sales Analysis
• 8.10. Trulicity
  • 8.10.1. Overview & Patent Insight
  • 8.10.2. Pricing & Dosage Insight
  • 8.10.3. Sales Analysis
• 8.11. Ozempic
  • 8.11.1. Overview & Patent Insight
  • 8.11.2. Pricing & Dosage Insight
  • 8.11.3. Sales Analysis
• 8.12. Wegovy
  • 8.12.1. Overview & Patent Insight
  • 8.12.2. Pricing & Dosage Insight
  • 8.12.3. Sales Analysis
• 8.13. Tresiba
  • 8.13.1. Overview & Patent Insight
  • 8.13.2. Pricing & Dosage Insight
  • 8.13.3. Sales Analysis
• 8.14. Rybelsus
  • 8.14.1. Overview & Patent Insight
  • 8.14.2. Pricing & Dosage Insight
  • 8.14.3. Sales Analysis
• 8.15. Xultophy
  • 8.15.1. Overview & Patent Insight
  • 8.15.2. Pricing & Dosage Insight
  • 8.15.3. Sales Analysis
• 8.16. Victoza
  • 8.16.1. Overview & Patent Insight
  • 8.16.2. Pricing & Dosage Insight
  • 8.16.3. Sales Analysis
• 8.17. Ryzodeg
  • 8.17.1. Overview & Patent Insight
  • 8.17.2. Pricing & Dosage Insight
  • 8.17.3. Sales Analysis
• 8.18. Fiasp
  • 8.18.1. Overview & Patent Insight
  • 8.18.2. Pricing & Dosage Insight
  • 8.18.3. Sales Analysis
• 8.19. Lantus
  • 8.19.1. Overview & Patent Insight
  • 8.19.2. Pricing & Dosage Insight
  • 8.19.3. Sales Analysis
• 8.20. Toujeo
  • 8.20.1. Overview & Patent Insight
  • 8.20.2. Pricing & Dosage Insight
  • 8.20.3. Sales Analysis

9. Peptide Therapeutics Development Technologies Platform

• 9.1. Biodrug Design Accelerator - Fujitsu/PeptiDream
• 9.2. T-Win® Technology - IO Biotech
• 9.3. Numatech - Numaferm
• 9.4. ProteinStudio - ProteinQure
• 9.5. The Magnifier NφΦ™ - Nuritas
• 9.6. PepPower - GenScript
• 9.7. Unnamed Peptide Platform - Zealand Pharma
• 9.8. PDPS (Peptide Discovery Platform System) - PeptiDream
• 9.9. Veneno Suite - Veneno Technologies
• 9.10. SmartDepot™ Technology - Peptron
• 9.11. Bicycles - Bicycle Therapeutics
• 9.12. RALA Technolgy - pHion Therapeutics
• 9.13. Discovery Platform - Orbit Discovery
• 9.14. Imotopes - Imcyse
• 9.15. Nautilus - Peptilogics
• 9.16. Swarm Intelligence 2.0 - Pepticom
• 9.17. streaMLine Platform - Gubra
• 9.18. Precision Endocrine Peptides (PEPs) - MBX Biosciences
• 9.19. pHLIP (pH-Low Insertion Peptides) - pHLIP
• 9.20. alphalex - Cybrexa

10. Cyclic Peptides Clinical Trials Insight By Country, Indication & Phase

• 10.1. Research
• 10.2. Preclinical
• 10.3. Phase-I
• 10.4. Phase-I/II
• 10.5. Phase-II
• 10.6. Phase-II/III
• 10.7. Phase-III
• 10.8. Preregistration
• 10.9. Registered
• 10.10. Marketed

11. Peptide Hormones Clinical Trials Insight By Country, Indication & Phase

• 11.1. Research
• 11.2. Preclinical
• 11.3. Phase-I
• 11.5. Phase-I/II
• 11.6. Phase-II
• 11.7. Phase-II/III
• 11.8. Phase-III
• 11.9. Preregistration
• 11.10. Registered
• 11.11. Marketed

12. Peptides Clinical Trials Insight By Country, Indication & Phase

• 12.1. Research
• 12.2. Preclinical
• 12.3. Phase-I
• 12.4. Phase-I/II
• 12.5. Phase-II
• 12.6. Phase-II/III
• 12.7. Phase-III
• 12.8. Preregistration
• 12.9. Registered
• 12.10. Marketed

13. Glucagon-Like Peptides Clinical Trials Insight By Country, Indication & Phase

• 13.1. Preclinical
• 13.2. Phase-I
• 13.3. Phase-I/II
• 13.4. Phase-II
• 13.5. Phase-III
• 13.6. Marketed

14. Oligopeptides Clinical Trials Insight By Country, Indication & Phase

• 14.1. Research
• 14.2. Preclinical
• 14.3. Phase-I
• 14.4. Phase-I/II
• 14.5. Phase-II
• 14.6. Phase-II/III
• 14.7. Phase-III
• 14.8. Registered
• 14.9. Marketed

15. Lipopeptides Clinical Trials Insight By Country, Indication & Phase

• 15.1. Research
• 15.2. Preclinical
• 15.3. Phase-II
• 15.4. Marketed

16. Dipeptides Clinical Trials Insight By Country, Indication & Phase

• 16.1. Research
• 16.2. Preclinical
• 16.3. Phase-I
• 16.4. Phase-II
• 16.5. Phase-III
• 16.6. Registered
• 16.7. Marketed

17. Depsipeptides Clinical Trials Insight By Country, Indication & Phase

• 17.1. Preclinical
• 17.2. Phase-I
• 17.3. Phase-II
• 17.4. Marketed

18. Glycopeptides Clinical Trials Insight By Country, Indication & Phase

• 18.1. Preclinical
• 18.2. Phase-I
• 18.3. Phase-I/II
• 18.5. Phase-II
• 18.6. Phase-III
• 18.8. Marketed

19. Peptide Vaccines Clinical Trials Insight By Country, Indication & Phase

• 19.1. Preclinical
• 19.2. Phase-I/II
• 19.3. Phase-II
• 19.4. Phase-III
• 19.5. Registered
• 19.6. Marketed

20. Peptide Fragments Clinical Trials Insight By Country, Indication & Phase

• 20.1. Preclinical
• 20.2. Phase-I
• 20.3. Phase-II
• 20.4. Phase-III
• 20.5. Preregistration
• 20.6. Registered
• 20.7. Marketed

21. Opioid Peptides Clinical Trials Insight By Country, Indication & Phase

• 21.1. Research
• 21.2. Preclinical
• 21.3. Phase-I
• 21.4. Phase-II
• 21.5. Preregistration
• 21.6. Registered
• 21.7. Marketed

22. Natriuretic Peptides Clinical Trials Insight By Country, Indication & Phase

• 22.1. Preclinical
• 22.2. Phase-I
• 22.3. Phase-II
• 22.4. Phase-II/III
• 22.5. Phase-III
• 22.6. Marketed

23. Neuropeptides Clinical Trials Insight By Country, Indication & Phase

• 23.1. Research
• 23.2. Preclinical
• 23.3. Phase-I
• 23.4. Phase-I/II
• 23.5. Phase-II
• 23.6. Marketed

24. Antimicrobial Cationic Peptides Clinical Trials Insight By Country, Indication & Phase

• 24.1. Preclinical
• 24.2. Phase-I
• 24.3. Phase-III

25. Peptide Hydrolases Clinical Trials Insight By Country, Indication & Phase

• 25.1. Phase-II

26. Peptide Aptamers

• 26.1. Research
• 26.2. Preclinical
• 26.3. Phase-I
• 26.4. Phase-II

27. Intercellular Signalling Peptides Clinical Trials Insight By Country, Indication & Phase

• 27.1. Phase-II

28. Peptide Antibiotics Clinical Trials Insight By Country, Indication & Phase

• 28.1. Phase-I

29. Peptide Drug Conjugates Clinical Trials Insight By Country, Indication & Phase

• 29.1. Preclinical

30. Bicyclic Peptides Clinical Trials Insight By Country, Indication & Phase

• 30.1. Preclinical

31. Multiple Peptides Clinical Trials Insight By Country, Indication & Phase

• 31.1. Research
• 31.2. Preclinical
• 31.3. Phase-I
• 31.4. Phase-I/II
• 31.5. Phase-II
• 31.6. Preregistration
• 31.7. Registered
• 31.8. Marketed

32. Competitive Landscape

• 32.1. AbbVie
• 32.2. Adocia
• 32.3. Amgen
• 32.4. Antlia Bioscience
• 32.5. AsclepiX Therapeutics
• 32.6. AstraZeneca
• 32.7. Bicycle Therapeutics
• 32.8. Biohaven Labs
• 32.9. Bristol-Myers Squibb
• 32.10. Carmot Therapeutics
• 32.11. Eli Lilly and Company
• 32.12. Ferring Pharmaceuticals
• 32.13. Gan&Lee Pharmaceuticals
• 32.14. GEROPHARM
• 32.15. Hanmi Pharmaceutical
• 32.16. HEC Pharm
• 32.17. Heidelberg Pharma AG
• 32.18. ImCyse
• 32.19. Janux Therapeutics
• 32.20. Kine Sciences
• 32.21. Lactocore
• 32.22. Maxwell Biosciences
• 32.23. Merck & Co
• 32.24. Novartis
• 32.25. Novo Nordisk
• 32.26. Oryn Therapeutics
• 32.27. Palatin Technologies
• 32.28. PeptiDream
• 32.29. Pfizer
• 32.30. Priavoid
• 32.31. Primary Peptides
• 32.32. Protagonist Therapeutics
• 32.33. Roche
• 32.34. Sanofi
• 32.35. Sapience Therapeutics
• 32.36. Seagen
• 32.37. Shaanxi Micot Technology Co
• 32.38. Stuart Therapeutics
• 32.39. Takeda
• 32.40. Zealand Pharma

List of Figures

• Figure 1-1: Landmarks in Peptides Drugs Market
• Figure 3-1: Pro00013585 Phase II Study - Initiation & Completion Years
• Figure 3-2: STUDY0000567 Phase II Study - Initiation & Completion Years
• Figure 3-3: NCT05378672 Phase III Study - Initiation & Completion Years
• Figure 3-4: ZP4207-21052 Phase III Study - Initiation & Completion Years
• Figure 3-5: GLSI-21-01 Phase III Study - Initiation & Completion Years
• Figure 3-6: IO102-IO103-013 Phase III Study - Initiation & Completion Years
• Figure 3-7: NCT06091748 Phase II Study - Initiation & Completion Years
• Figure 3-8: PMC67199 Phase I Study - Initiation & Completion Years
• Figure 3-9: ACW-1221958-1 Phase II Study - Initiation & Completion Years
• Figure 3-10: NCT05841095 Phase I/II Study - Initiation & Completion Years
• Figure 3-11: NCT05340790 Phase I Study - Initiation & Completion Years
• Figure 3-12: IR902-007 Phase I Study - Initiation & Completion Years
• Figure 3-13: ISEMIS Phase I/II Study - Initiation & Completion Years
• Figure 3-14: YN011-301 Phase II/III Study - Initiation & Completion Years
• Figure 3-15: SCW0502-1031 Phase III Study - Initiation & Completion Years
• Figure 3-16: NCT05202353 Phase I Study - Initiation & Completion Years
• Figure 3-17: NCT04305002 Phase II Study - Initiation & Completion Years
• Figure 3-18: NCT05189210 Phase II Study - Initiation & Completion Years
• Figure 3-19: ALZ-C-001 Phase II Study - Initiation & Completion Years
• Figure 3-20: ELViS-FA Phase I/II Study - Initiation & Completion Years
• Figure 3-21: NCT05634876 Phase II Study - Initiation & Completion Years
• Figure 4-1: CUV104 Phase II Study - Initiation & Completion Years
• Figure 4-2: CUV152 Phase II Study - Initiation & Completion Years
• Figure 4-3: Peptide-Drug Conjugate Structure
• Figure 4-4: NCT04706962 Phase I Study - Initiation & Completion Years
• Figure 4-5: MLB-PK-001 Early Phase I Study - Initiation & Completion Year
• Figure 4-6: ANGLeD Phase III Study - Initiation & Completion Years
• Figure 4-7: CA209-8TX Phase I/II Study - Initiation & Completion Years
• Figure 4-8: CLAUDE/EOCRC1-22 Phase II Study - Initiation & Completion Years
• Figure 4-9: COVENANT Phase III Study - Initiation & Completion Years
• Figure 4-10: EGRABIS1 Phase II Study - Initiation & Completion Years
• Figure 4-11: GLIMP Phase II Study - Initiation & Completion Years
• Figure 4-12: NCT05530577 Phase II Study - Initiation & Completion Years
• Figure 5-1: Global - Peptide Therapeutic Market Size (US$ Billion), 2022 - 2029
• Figure 5-2: Global - Peptide Oncology Drugs Market Size (US$ Billion), 2022 - 2029
• Figure 5-3: Ongoing Trends in Peptide Drugs Market
• Figure 5-4: Future Growth Avenues in Peptide Drugs Market
• Figure 6-1: China - Estimated Diabetes Population (Million), 2021 & 2030
• Figure 6-2: India - Estimated Diabetes Population (Million), 2021 & 2030
• Figure 6-3: ME - Estimated Diabetes Population in Saudi Arabia & UAE (Million), 2021 & 2030
• Figure 6-4: Canada - Estimated Diabetes Population (Million), 2021 & 2030
• Figure 7-1: Global - Peptides Clinical Trials by Country (Numbers), 2023 Till 2029
• Figure 7-2: Global - Peptides Clinical Trials by Indication (Numbers), 2023 Till 2029
• Figure 7-3: Global - Peptide Clinical Trials by Phase (Numbers), 2023 till 2029
• Figure 7-4: Global - Cyclic Peptide Clinical Trials by Phase (Numbers), 2023 till 2029
• Figure 7-5: Global - Peptide Hormones Clinical Trials by Phase (Numbers), 2023 till 2029
• Figure 7-6: Global - Glucagon-Like Peptides Clinical Trials by Phase (Numbers), 2023 till 2029
• Figure 7-7: Global - Oligopeptides Clinical Trials by Phase (Numbers), 2023 till 2029
• Figure 7-8: Global - Lipopeptides Clinical Trials by Phase (Numbers), 2023 till 2029
• Figure 7-9: Global - Dipeptides Clinical Trials by Phase (Numbers), 2023 till 2029
• Figure 7-10: Global - Depsipeptides Clinical Trials by Phase (Numbers), 2023 till 2029
• Figure 7-11: Global - Glycopeptides Clinical Trials by Phase (Numbers), 2023 till 2029
• Figure 7-12: Global - Peptide Vaccines Clinical Trials by Phase (Numbers), 2023 till 2029
• Figure 7-13: Global - Peptide Fragments Clinical Trials by Phase (Numbers), 2023 till 2029
• Figure 7-14: Global - Opioid Peptides Clinical Trials by Phase (Numbers), 2023 till 2029
• Figure 7-15: Global - Natriuretic Peptides Clinical Trials by Phase (Numbers), 2023 till 2029
• Figure 7-16: Global - Neuropeptides Clinical Trials by Phase (Numbers), 2023 till 2029
• Figure 7-17: Global - Antimicrobial Cationic Peptides Clinical Trials by Phase (Numbers), 2023 till 2029
• Figure 7-18: Global - Peptide Aptamers Clinical Trials by Phase (Numbers), 2023 till 2029
• Figure 7-19: Global - Peptides Clinical Trials by Priority Status (Numbers), 2023 Till 2029
• Figure 7-20: Global - Peptides Clinical Trials by Therapy Class (Numbers), 2023 Till 2029
• Figure 8-1: US - Cost per Unit & Supply of Bylvay Oral Capsules (US$), November'2023
• Figure 8-2: US - Cost per Unit & Supply of Bylvay Oral Pellets (US$), November'2023
• Figure 8-3: EU - Cost per Unit & Supply of Bylvay Oral Capsules & Pellets (Eur/US$), November'2023
• Figure 8-4: Global - Quarterly Bylvay Sales (US$ Million), 2023
• Figure 8-5: NA - Quarterly Bylvay Sales (US$ Million), 2023
• Figure 8-6: Europe - Quarterly Bylvay Sales (US$ Million), 2023
• Figure 8-7: ROW - Quarterly Bylvay Sales (US$ Million), 2023
• Figure 8-8: Parsabiv - US Patents Expiration Years
• Figure 8-9: Parsabiv - Europe Patents Expiration Years
• Figure 8-10: Parsabiv - Cost per Unit & Supply (US$), November'2023
• Figure 8-11: Global - Annual Parsabiv Sales (US$ Million), 2019-2023
• Figure 8-12: US - Annual Parsabiv Sales (US$ Million), 2019-2023
• Figure 8-13: ROW - Annual Parsabiv Sales (US$ Million), 2019-2023
• Figure 8-14: Global - Quarterly Parsabiv Sales (US$ Million), 2023
• Figure 8-15: US - Quarterly Parsabiv Sales (US$ Million), 2023
• Figure 8-16: ROW - Quarterly Parsabiv Sales (US$ Million), 2023
• Figure 8-17: Global - Quarterly Parsabiv Sales (US$ Million), 2022
• Figure 8-18: US - Quarterly Parsabiv Sales (US$ Million), 2022
• Figure 8-19: ROW - Quarterly Parsabiv Sales (US$ Million), 2022
• Figure 8-20: Bydureon - Year of Approval and Expiry of Patents for Injection
• Figure 8-21: Bydureon - Year of Approval and Expiry of Patents for Injection
• Figure 8-22: Bydureon BCise - Cost per Unit & Supply (US$), November'2023
• Figure 8-23: Global - Annual Bydureon Sales (US$ Million), 2019-2023
• Figure 8-24: US - Annual Bydureon Sales (US$ Million), 2019-2023
• Figure 8-25: Europe - Annual Bydureon Sales (US$ Million), 2019-2023
• Figure 8-26: EM - Annual Bydureon Sales (US$ Million), 2019-2023
• Figure 8-27: ROW - Annual Bydureon Sales (US$ Million), 2019-2023
• Figure 8-28: Global - Quarterly Bydureon Sales (US$ Million), 2023
• Figure 8-29: US - Quarterly Bydureon Sales (US$ Million), 2023
• Figure 8-30: Europe - Quarterly Bydureon Sales (US$ Million), 2023
• Figure 8-31: EM - Quarterly Bydureon Sales (US$ Million), 2023
• Figure 8-32: Global - Quarterly Bydureon Sales (US$ Million), 2022
• Figure 8-33: US - Quarterly Bydureon Sales (US$ Million), 2022
• Figure 8-34: Europe - Quarterly Bydureon Sales (US$ Million), 2022
• Figure 8-35: EM - Quarterly Bydureon Sales (US$ Million), 2022
• Figure 8-36: Linzess - Cost per Unit & Supply (US$), November'2023
• Figure 8-37: Linzess - Dosage by Indication (mcg)
• Figure 8-38: Global - Annual Linzess Sales (US$ Million), 2020-2023
• Figure 8-39: US - Annual Linzess Sales (US$ Million), 2020-2023
• Figure 8-40: ROW - Annual Linzess Sales (US$ Million), 2019-2023
• Figure 8-41: Global - Quarterly Linzess Sales (US$ Million), 2023
• Figure 8-42: US - Quarterly Linzess Sales (US$ Million), 2023
• Figure 8-43: ROW - Quarterly Linzess Sales (US$ Million), 2023
• Figure 8-44: Global - Quarterly Linzess Sales (US$ Million), 2022
• Figure 8-45: US - Quarterly Linzess Sales (US$ Million), 2022
• Figure 8-46: ROW - Quarterly Linzess Sales (US$ Million), 2022
• Figure 8-47: Increlex - US & EU Patent Expiry Years
• Figure 8-48: Increlex - Cost per Unit & Supply (US$), November'2023
• Figure 8-49: Global - Annual Increlex Sales (US$ Million), 2019-2023
• Figure 8-50: Global - Quarterly Increlex Sales (US$ Million), 2023
• Figure 8-51: Global - Quarterly Increlex Sales (US$ Million), 2022
• Figure 8-52 : Terlivaz - Dosing Chart
• Figure 8-53: Global - Quarterly Terlivaz Sales (US$ Million), 2023
• Figure 8-54: Empaveli - Cost per Unit & Supply (US$), November'2023
• Figure 8-55: Empaveli - Cost of Monthly & Yearly Treatment (US$), November'2023
• Figure 8-56: Global - Annual Empaveli Sales (US$ Million), 2021-2023
• Figure 8-57: US - Annual Empaveli Sales (US$ Million), 2021-2023
• Figure 8-58: ROW - Annual Empaveli Sales (US$ Million), 2021-2023
• Figure 8-59: Global - Quarterly Increlex Sales (US$ Million), 2023
• Figure 8-60: US - Quarterly Empaveli Sales (US$ Million), 2023
• Figure 8-61: ROW - Quarterly Empaveli Sales (US$ Million), 2023
• Figure 8-62: Global - Quarterly Increlex Sales (US$ Million), 2022
• Figure 8-63: US - Annual Empaveli Sales (US$ Million), 2022
• Figure 8-64: ROW - Annual Empaveli Sales (US$ Million), 2022
• Figure 8-65: Voxzogo - Cost per Unit & Supply (US$), November'2023
• Figure 8-66: Global - Annual Voxzogo Sales (US$ Million), 2021-2023
• Figure 8-67: Global - Quarterly Voxzogo Sales (US$ Million), 2023
• Figure 8-68: Global - Quarterly Voxzogo Sales (US$ Million), 2022
• Figure 8-69: Global - Annual Imcivree Sales (US$ Million), 2021-2023
• Figure 8-70: Global - Quarterly Imcivree Sales (US$ Million), 2023
• Figure 8-71: Global - Quarterly Imcivree Sales (US$ Million), 2022
• Figure 8-72: Voxzogo - Cost per Unit & Supply (US$), November'2023
• Figure 8-73: Global - Annual Trulicity Sales (US$ Million), 2019-2023
• Figure 8-74: Global - Quarterly Trulicity Sales (US$ Million), 2023
• Figure 8-75: Global - Quarterly Trulicity Sales (US$ Million), 2022
• Figure 8-76: Ozempic - Cost per Unit & Supply (US$), November'2023
• Figure 8-77: Ozempic - Initiation and Increment Doses (mg/week)
• Figure 8-78: Global - Annual Ozempic Sales (US$ Million), 2019-2023
• Figure 8-79: NA - Annual Ozempic Sales (US$ Million), 2019-2023
• Figure 8-80: EMEA - Annual Ozempic Sales (US$ Million), 2019-2023
• Figure 8-81: China - Annual Ozempic Sales (US$ Million), 2019-2023
• Figure 8-82: ROW - Annual Ozempic Sales (US$ Million), 2019-2023
• Figure 8-83: Global - Quarterly Ozempic Sales (US$ Million), 2023
• Figure 8-84: NA - Quarterly Ozempic Sales (US$ Million), 2023
• Figure 8-85: EMEA - Quarterly Ozempic Sales (US$ Million), 2023
• Figure 8-86: China - Quarterly Ozempic Sales (US$ Million), 2023
• Figure 8-87: ROW - Quarterly Ozempic Sales (US$ Million), 2023
• Figure 8-88: Global - Quarterly Ozempic Sales (US$ Million), 2022
• Figure 8-89: NA - Quarterly Ozempic Sales (US$ Million), 2022
• Figure 8-90: EMEA - Quarterly Ozempic Sales (US$ Million), 2022
• Figure 8-91: China - Quarterly Ozempic Sales (US$ Million), 2022
• Figure 8-92: ROW - Quarterly Ozempic Sales (US$ Million), 2022
• Figure 8-93: Wegovy - Cost per Unit & Supply of 0.25mg, 0.5mg and 1mg Solutions (US$), November'2023
• Figure 8-94: Wegovy - Cost per Unit & Supply of 1.7mg, and 2.4mg Solutions (US$), November'2023
• Figure 8-95: Global - Annual Wegovy Sales (US$ Million), 2021-2023
• Figure 8-96: NA - Annual Wegovy Sales (US$ Million), 2021-2023
• Figure 8-97: EMEA - Annual Wegovy Sales (US$ Million), 2021-2023
• Figure 8-98: Global - Quarterly Wegovy Sales (US$ Million), 2023
• Figure 8-99: NA - Quarterly Wegovy Sales (US$ Million), 2023
• Figure 8-100: EMEA - Quarterly Wegovy Sales (US$ Million), 2023
• Figure 8-101: Global - Quarterly Wegovy Sales (US$ Million), 2022
• Figure 8-102: NA - Quarterly Wegovy Sales (US$ Million), 2022
• Figure 8-103: EMEA - Quarterly Wegovy Sales (US$ Million), 2022
• Figure 8-104: Tresiba - Cost per Unit & Supply of 100 units/mL Solution (US$), November'2023
• Figure 8-105: Tresiba - Cost per Unit & Supply of 200 units/mL Solution (US$), November'2023
• Figure 8-106: Insulin degludec - Cost per Unit & Supply of 100 units/mL Solution (US$), November'2023
• Figure 8-107: Global - Annual Tresiba Sales (US$ Million), 2019-2023
• Figure 8-108: NA - Annual Tresiba Sales (US$ Million), 2019-2023
• Figure 8-109: EMEA - Annual Tresiba Sales (US$ Million), 2019-2023
• Figure 8-110: China - Annual Tresiba Sales (US$ Million), 2019-2023
• Figure 8-111: ROW - Annual Tresiba Sales (US$ Million), 2019-2023
• Figure 8-112: Global - Quarterly Tresiba Sales (US$ Million), 2023
• Figure 8-113: NA - Quarterly Tresiba Sales (US$ Million), 2023
• Figure 8-114: EMEA - Quarterly Tresiba Sales (US$ Million), 2023
• Figure 8-115: China - Quarterly Tresiba Sales (US$ Million), 2023
• Figure 8-116: ROW - Quarterly Tresiba Sales (US$ Million), 2023
• Figure 8-117: Global - Quarterly Tresiba Sales (US$ Million), 2022
• Figure 8-118: NA - Quarterly Tresiba Sales (US$ Million), 2022
• Figure 8-119: EMEA - Quarterly Tresiba Sales (US$ Million), 2022
• Figure 8-120: China - Quarterly Tresiba Sales (US$ Million), 2022
• Figure 8-121: ROW - Quarterly Tresiba Sales (US$ Million), 2022
• Figure 8-122: Rybelsus - Cost per Unit & Supply (US$), November'2023
• Figure 8-123: Global - Annual Rybelsus Sales (US$ Million), 2019-2023
• Figure 8-124: NA - Annual Rybelsus Sales (US$ Million), 2019-2023
• Figure 8-125: EMEA - Annual Rybelsus Sales (US$ Million), 2019-2023
• Figure 8-126: China - Annual Rybelsus Sales (US$ Million), 2019-2023
• Figure 8-127: ROW - Annual Rybelsus Sales (US$ Million), 2019-2023
• Figure 8-128: Global - Quarterly Rybelsus Sales (US$ Million), 2023
• Figure 8-129: NA - Quarterly Rybelsus Sales (US$ Million), 2023
• Figure 8-130: EMEA - Quarterly Rybelsus Sales (US$ Million), 2023
• Figure 8-131: China - Quarterly Rybelsus Sales (US$ Million), 2023
• Figure 8-132: ROW - Quarterly Rybelsus Sales (US$ Million), 2023
• Figure 8-133: Global - Quarterly Rybelsus Sales (US$ Million), 2022
• Figure 8-134: NA - Quarterly Rybelsus Sales (US$ Million), 2022
• Figure 8-135: EMEA - Quarterly Rybelsus Sales (US$ Million), 2022
• Figure 8-136: China - Quarterly Rybelsus Sales (US$ Million), 2022
• Figure 8-137: ROW - Quarterly Rybelsus Sales (US$ Million), 2022
• Figure 8-138: Xultophy - Cost per Unit & Supply (US$), November'2023
• Figure 8-139: Global - Annual Xultophy Sales (US$ Million), 2019-2023
• Figure 8-140: NA - Annual Xultophy Sales (US$ Million), 2019-2023
• Figure 8-141: EMEA - Annual Xultophy Sales (US$ Million), 2019-2023
• Figure 8-142: China - Annual Xultophy Sales (US$ Million), 2019-2023
• Figure 8-143: ROW - Annual Xultophy Sales (US$ Million), 2019-2023
• Figure 8-144: Global - Quarterly Xultophy Sales (US$ Million), 2023
• Figure 8-145: NA - Quarterly Xultophy Sales (US$ Million), 2023
• Figure 8-146: EMEA - Quarterly Xultophy Sales (US$ Million), 2023
• Figure 8-147: China - Quarterly Xultophy Sales (US$ Million), 2023
• Figure 8-148: ROW - Quarterly Xultophy Sales (US$ Million), 2023
• Figure 8-149: Global - Quarterly Xultophy Sales (US$ Million), 2022
• Figure 8-150: NA - Quarterly Xultophy Sales (US$ Million), 2022
• Figure 8-151: EMEA - Quarterly Xultophy Sales (US$ Million), 2022
• Figure 8-152: China - Quarterly Xultophy Sales (US$ Million), 2022
• Figure 8-153: ROW - Quarterly Xultophy Sales (US$ Million), 2022
• Figure 8-154: Victoza - Cost per Unit & Supply (US$), November'2023
• Figure 8-155: Global - Annual Victoza Sales (US$ Million), 2019-2023
• Figure 8-156: North America - Annual Victoza Sales (US$ Million), 2019-2023
• Figure 8-157: EMEA - Annual Victoza Sales (US$ Million), 2019-2023
• Figure 8-158: China - Annual Victoza Sales (US$ Million), 2019-2023
• Figure 8-159: ROW - Annual Victoza Sales (US$ Million), 2019-2023
• Figure 8-160: Global - Quarterly Victoza Sales (US$ Million), 2023
• Figure 8-161: North America - Quarterly Victoza Sales (US$ Million), 2023
• Figure 8-162: EMEA - Quarterly Victoza Sales (US$ Million), 2023
• Figure 8-163: China - Quarterly Victoza Sales (US$ Million), 2023
• Figure 8-164: ROW - Quarterly Victoza Sales (US$ Million), 2023
• Figure 8-165: Global - Quarterly Victoza Sales (US$ Million), 2022
• Figure 8-166: North America - Quarterly Victoza Sales (US$ Million), 2022
• Figure 8-167: EMEA - Quarterly Victoza Sales (US$ Million), 2022
• Figure 8-168: China - Quarterly Victoza Sales (US$ Million), 2022
• Figure 8-169: ROW - Quarterly Victoza Sales (US$ Million), 2022
• Figure 8-170: Global - Annual Victoza Sales (US$ Million), 2019-2023
• Figure 8-171: EMEA - Annual Victoza Sales (US$ Million), 2019-2023
• Figure 8-172: China - Annual Victoza Sales (US$ Million), 2019-2023
• Figure 8-173: ROW - Annual Victoza Sales (US$ Million), 2019-2023
• Figure 8-174: Global - Quarterly Victoza Sales (US$ Million), 2023
• Figure 8-175: EMEA - Quarterly Victoza Sales (US$ Million), 2023
• Figure 8-176: China - Quarterly Victoza Sales (US$ Million), 2023
• Figure 8-177: ROW - Quarterly Victoza Sales (US$ Million), 2023
• Figure 8-178: Global - Quarterly Victoza Sales (US$ Million), 2022
• Figure 8-179: EMEA - Quarterly Victoza Sales (US$ Million), 2022
• Figure 8-180: China - Quarterly Victoza Sales (US$ Million), 2022
• Figure 8-181: ROW - Quarterly Victoza Sales (US$ Million), 2022
• Figure 8-182: Fiasp - Cost per Unit & Supply (US$), November'2023
• Figure 8-183: Global - Annual Fiasp Sales (US$ Million), 2019-2023
• Figure 8-184: NA - Annual Fiasp Sales (US$ Million), 2019-2023
• Figure 8-185: EMEA - Annual Fiasp Sales (US$ Million), 2019-2023
• Figure 8-186: ROW - Annual Fiasp Sales (US$ Million), 2019-2023
• Figure 8-187: Global - Quarterly Fiasp Sales (US$ Million), 2023
• Figure 8-188: NA - Quarterly Fiasp Sales (US$ Million), 2023
• Figure 8-189: EMEA - Quarterly Fiasp Sales (US$ Million), 2023
• Figure 8-190: ROW - Quarterly Fiasp Sales (US$ Million), 2023
• Figure 8-191: Global - Quarterly Fiasp Sales (US$ Million), 2022
• Figure 8-192: NA - Quarterly Fiasp Sales (US$ Million), 2022
• Figure 8-193: EMEA - Quarterly Fiasp Sales (US$ Million), 2022
• Figure 8-194: ROW - Quarterly Fiasp Sales (US$ Million), 2022
• Figure 8-195: Lantus - Cost per Unit & Supply (US$), November'2023
• Figure 8-196: Insulin Glargine & Insulin Glargine-yfgn - Cost per Unit & Supply (US$), November'2023
• Figure 8-197: Global - Annual Lantus Sales (US$ Million), 2019-2023
• Figure 8-198: US - Annual Lantus Sales (US$ Million), 2019-2023
• Figure 8-199: Europe - Annual Lantus Sales (US$ Million), 2019-2023
• Figure 8-200: ROW - Annual Lantus Sales (US$ Million), 2019-2023
• Figure 8-201: Global - Quarterly Lantus Sales (US$ Million), 2023
• Figure 8-202: US - Quarterly Lantus Sales (US$ Million), 2023
• Figure 8-203: Europe - Quarterly Lantus Sales (US$ Million), 2023
• Figure 8-204: ROW - Quarterly Lantus Sales (US$ Million), 2023
• Figure 8-205: Global - Quarterly Lantus Sales (US$ Million), 2022
• Figure 8-206: US - Quarterly Lantus Sales (US$ Million), 2022
• Figure 8-207: Europe - Quarterly Lantus Sales (US$ Million), 2022
• Figure 8-208: ROW - Quarterly Lantus Sales (US$ Million), 2022
• Figure 8-209: Toujeo - US Patent Acceptance & Expiration Years
• Figure 8-210: Toujeo - Cost per Unit & Supply (US$), November'2023
• Figure 8-211: Global - Annual Toujeo Sales (US$ Million), 2019-2023
• Figure 8-212: US - Annual Toujeo Sales (US$ Million), 2019-2023
• Figure 8-213: Europe - Annual Toujeo Sales (US$ Million), 2019-2023
• Figure 8-214: ROW - Annual Toujeo Sales (US$ Million), 2019-2023
• Figure 8-215: Global - Quarterly Toujeo Sales (US$ Million), 2023
• Figure 8-216: US - Quarterly Toujeo Sales (US$ Million), 2023
• Figure 8-217: Europe - Quarterly Toujeo Sales (US$ Million), 2023
• Figure 8-218: ROW - Quarterly Toujeo Sales (US$ Million), 2023
• Figure 8-219: Global - Quarterly Toujeo Sales (US$ Million), 2022
• Figure 8-220: US - Quarterly Toujeo Sales (US$ Million), 2022
• Figure 8-221: Europe - Quarterly Toujeo Sales (US$ Million), 2022
• Figure 8-222: ROW - Quarterly Toujeo Sales (US$ Million), 2022
• Figure 9-1: Biodrug Design Accelerator - Technical Benefits
• Figure 9-2: Biodrug Design Accelerator - Technical Benefits
• Figure 9-3: IO Biotech - T-win Technology
• Figure 9-4: Numatech - Numaferm Platform
• Figure 9-5: Nuritas - Scientific Achievements of Magnifier NφΦ Bioactive Peptide Discovery Platform
• Figure 9-6: Nuritas - The Magnifier NφΦ Bioactive Peptide Discovery Process
• Figure 9-7: Nuritas - The Magnifier NφΦ Bioactive Peptide Results
• Figure 9-8: GenScript - PepPower Technology
• Figure 9-9: PeptiDream - PDPS Outline
• Figure 9-10: PeptiDream - PDPS Outline
• Figure 9-11: PeptiDream - PDPS Features
• Figure 9-12: Benefits of DRPs as Drug Molecule Scaffold
• Figure 9-13: Veneno Technologies - Veneno Suite Components
• Figure 9-14: Veneno Technologies - Veneno Suite Process
• Figure 9-15: Peptron - SmartDepot™ Features
• Figure 9-16: Peptron - SmartDepot™ Manufacturing Scheme
• Figure 9-17: Bicycle Therapeutics - Bicycles Key Properties
• Figure 9-18: Bicycle Therapeutics - Bicycles Key Properties
• Figure 9-19: pHion Therapeutics - RALA Nanoparticles Advantages
• Figure 9-20: pHion Therapeutics - RALA Nanoparticles BENEFITS
• Figure 9-21: Orbit Discovery - Orbit Peptide Display Engine
• Figure 9-22: Benefits of Imotopes over Current Therapies
• Figure 9-23: Peptilogics - Peptide Development Process
• Figure 9-24: Peptilogics - Nautilus Features
• Figure 9-25: Pepticom - Swarm Intelligence 2.0 AI platform
• Figure 9-26: Cybrexa - alphalex Selective Tumor Cell Targeting

List of Tables

• Table 1-1: Landmarks in Peptides Drugs Market
• Table 6-1: US - Recent FDA Designations for Peptide Drug Candidates
• Table 8-1: Bylvay - Recommended Dosage for 40 mcg/kg/day
• Table 8-2: Parsabiv - Recommended Schedule for Monitoring Corrected Serum Calcium and Parathyroid Hormone Levels during Treatment
• Table 8-3: Voxzogo - Recommended Daily Dosage and Injection Volume
• Table 8-4: Wegovy - Recommended Dosage Regimen for Adults
• Table 8-5: Wegovy - Recommended Dosage Regimen for Pediatric Patients Aged 12 Years and Older
• Table 9-1: GenScript - PepPower™ Platform Advantages